Clinical Trials for Mesothelioma Patients—A Study of Azacitidine in combination with Temo/Azac: Description
Read the description for a current clinical trial about the use of a Phase I dose study of Azacitidine in combination with Temo/Azac for patients with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
The primary objective of the study is to determine the clinical and laboratory toxicities as well as acceptability/tolerance of this dose schedule of combined drug treatment with temozolomide and azacitidine.
Secondary objectives include determination of biochemical response to azacitidine as defined as change in methylation status. We will specifically be looking at changes in genome wide methylation patterns as determined by two high-throughput platforms:
A single nucleotide polymorphism chip-based method (MSNP) for genome wide epigenetic profiling
CpG island promoter arrays will be performed to focus on promoter methylation status.
Courtesy of ClinicalTrials.gov, a service of the U.S. National Institutes of Health
If you or a loved one has been diagnosed with an Asbestos illness like mesothelioma, lung cancer or asbestosis, complete the form on this page to get a FREE and prompt review of your case by a leading Asbestos attorney. Weitz & Luxenberg is a leading mesothelioma law firm with a substantial history of success in asbestos exposure cases.